HFSA Highlights Late-Breaking Heart Failure Clinical Research
Washington, D.C., September 20, 2026 The Heart Failure Society of America (HFSA) has announced the late-breaking clinical research program...
Phase IIb
Advertisement
Accro Bioscience Advances AC-101 in Ulcerative Colitis
New York, United States, September 20, 2026 Accro Bioscience has announced that the first patient has been dosed in...
Mabwell Reports 9MW1911 COPD Phase Ib/IIa Results
Shanghai, China, September 4, 2026 Mabwell (Shanghai) Bioscience Co., Ltd. has announced Phase Ib/IIa clinical results for its investigational...
SciSparc Pursues FDA Orphan Drug Designation for SCI-110 in Tourette Syndrome
Tel Aviv, Israel, September 2, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. is pursuing U.S....
Advertisement
